1-{3'-Fluoro-4'-[1-methyl-5-((R)-1- phenyl-ethoxycarbonylamino)-1H-[1,2,3]triazole-4-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid;

{5-[4'-(1-Methanesulfonylaminocarbonyl-cyclopropyl)-biphenyl-4-yl]-3-methyl-3H-[1,2,3]triazol-4-yl}-carbamic acid (R)-1-phenyl-ethyl ester;

{5-[4'-(1-Methanesulfonylaminocarbonyl-cyclopropyl)-biphenyl-4-yl]-3-methyl-3H-[1,2,3]triazol-4-yl}-carbamic acid (R)-1-(3-trifluoromethyl-phenyl)-ethyl ester; or

(4-{4-[1-Methyl-5-((R)-1-phenyl-ethoxycarbonylamino)-1H-[1,2,3]triazol-4-yl]-phenyl}-cyclohexyl)-acetic acid.

12. A compound according to any one of claims 1 to 11 for use as a therapeutically active substance.

13. A pharmaceutical composition, comprising a therapeutically effective amount of a compound in accordance with any one of claims 1 to 11 and a therapeutically inert carrier.

14. The use of a compound according to any one of claims 1 to 11 for the treatment or prophylaxis of pulmonary fibrosis.

15. The use of a compound according to any one of claims 1 to 11 for the preparation of a medicament for the treatment or prophylaxis of pulmonary fibrosis.

16. A compound according to any one of claims 1 to 11 for the treatment or prophylaxis of pulmonary fibrosis.

17. A method for the treatment or prophylaxis of pulmonary fibrosis, which method comprises the step of administering an effective amount of a compound as defined in any one of claims 1 to 11 to a patient in need thereof.

~~18. The invention as hereinbefore described.~~